乳腺癌多基因阵列表达谱检测与个体化治疗

Multi-gene assay profiling testing and individualized therapy in breast cancer

乳腺癌是一种异质性疾病，多基因阵列表达谱检测可以更好地进行乳腺癌分子分型，预测患者的预后及治疗的疗效。两项前瞻性临床研究的结果验证了21基因复发分数及MammaPrint对早期乳腺癌患者预后的预测价值，通过筛选合适的患者，减少临床辅助化疗的过度应用，降低治疗的毒副作用。整合临床病理指标或开发与乳腺癌发生转移相关的新型多基因阵列表达谱，有助于进一步精确预测乳腺癌患者的转归，从而实现乳腺癌的个体化治疗。

Breast cancer is a heterogenetic disease. Multi-gene assay profiling can classify breast cancer into several molecular subtypes, which is better to predict disease prognosis and treatment response-Two prospective clinical trials validated the prognosis predictive value of 21 gene recurrence score and MammaPrint in early breast cancer, than to decrease the prescription of adjuvant chemotherapy and avoid side effect of chemotherapy- New multi-gene assay profiling integrating clinic-pathological factors or reflecting disease development and metastasis can help us predict disease outcome better, thus to achieve individualized therapy in breast cancer.